SIGA to Host Business Update Call on May 8, 2025 Following Release of First-Quarter 2025 Results
SIGA Technologies (NASDAQ: SIGA), a commercial-stage pharmaceutical company, has scheduled a business update conference call and webcast for May 8, 2025, at 4:30 P.M. ET. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire discussing the company's first-quarter 2025 results.
Investors can access the call through the company's website at www.siga.com or by dialing 1-800-717-1738 (domestic) or 1-646-307-1865 (international). A two-week replay will be available via phone using Conference ID: 1160299.
SIGA Technologies (NASDAQ: SIGA), un'azienda farmaceutica in fase commerciale, ha programmato una conferenza telefonica e webcast per l'aggiornamento aziendale il 8 maggio 2025 alle 16:30 ET. La chiamata vedrà la partecipazione del CEO Diem Nguyen e del CFO Daniel Luckshire, che discuteranno i risultati del primo trimestre 2025 dell'azienda.
Gli investitori potranno seguire la chiamata tramite il sito web dell'azienda all'indirizzo www.siga.com o chiamando il numero 1-800-717-1738 (nazionale) o 1-646-307-1865 (internazionale). Sarà disponibile una registrazione della chiamata per due settimane, consultabile telefonicamente con il Conference ID: 1160299.
SIGA Technologies (NASDAQ: SIGA), una compañía farmacéutica en etapa comercial, ha programado una conferencia telefónica y webcast para una actualización empresarial el 8 de mayo de 2025 a las 4:30 P.M. ET. La llamada contará con la participación del CEO Diem Nguyen y el CFO Daniel Luckshire, quienes discutirán los resultados del primer trimestre de 2025 de la empresa.
Los inversionistas pueden acceder a la llamada a través del sitio web de la compañía en www.siga.com o llamando al 1-800-717-1738 (nacional) o al 1-646-307-1865 (internacional). Habrá una repetición disponible por dos semanas vía telefónica usando el ID de conferencia: 1160299.
SIGA Technologies (NASDAQ: SIGA)는 상업 단계에 있는 제약 회사로, 2025년 5월 8일 오후 4시 30분(동부 표준시)에 사업 업데이트 전화 회의 및 웹캐스트를 예정하고 있습니다. 이번 통화에는 CEO 디엠 응우옌과 CFO 다니엘 럭셔이어가 참석하여 2025년 1분기 실적에 대해 논의할 예정입니다.
투자자들은 회사 웹사이트 www.siga.com을 통해 또는 국내 전화 1-800-717-1738, 국제 전화 1-646-307-1865로 접속할 수 있습니다. 전화 회의 ID: 1160299를 사용하여 2주간 전화로 다시 듣기 서비스도 제공됩니다.
SIGA Technologies (NASDAQ : SIGA), une entreprise pharmaceutique en phase commerciale, a programmé une conférence téléphonique et une diffusion en webcast pour une mise à jour commerciale le 8 mai 2025 à 16h30 ET. La conférence téléphonique mettra en vedette le PDG Diem Nguyen et le directeur financier Daniel Luckshire, qui discuteront des résultats du premier trimestre 2025 de l'entreprise.
Les investisseurs peuvent accéder à l'appel via le site web de l'entreprise à www.siga.com ou en composant le 1-800-717-1738 (domestique) ou le 1-646-307-1865 (international). Une rediffusion sera disponible pendant deux semaines par téléphone avec l'ID de conférence : 1160299.
SIGA Technologies (NASDAQ: SIGA), ein Pharmaunternehmen in der kommerziellen Phase, hat eine Telefonkonferenz und Webcast für ein Geschäftsupdate am 8. Mai 2025 um 16:30 Uhr ET angesetzt. An dem Anruf werden CEO Diem Nguyen und CFO Daniel Luckshire teilnehmen und die Ergebnisse des ersten Quartals 2025 des Unternehmens besprechen.
Investoren können über die Unternehmenswebsite www.siga.com oder telefonisch unter 1-800-717-1738 (national) oder 1-646-307-1865 (international) teilnehmen. Eine Wiederholung ist für zwei Wochen per Telefon mit der Konferenz-ID: 1160299 verfügbar.
- None.
- None.
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, May 8, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.
A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time.
Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers.
A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1160299. The archived webcast will be available in the Investor Relations section of the Company's website.
About SIGA
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit www.siga.com.
| Contacts: | |
| Suzanne Harnett | |
| sharnett@siga.com | |
| and | |
| Investors | Media |
| Jennifer Drew-Bear, Edison Group Jdrew-bear@edisongroup.com | Holly Stevens, CG Life hstevens@cglife.com |
FAQ
When will SIGA Technologies (SIGA) report Q1 2025 earnings?
How can I listen to SIGA's Q1 2025 earnings call?
Who will participate in SIGA's Q1 2025 earnings call?
How long will SIGA's Q1 2025 earnings call replay be available?
